-
761
-
762
-
763
-
764
-
765
-
766
-
767
Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
Published 2025-01-01“…Chandler Gandy,1 Shadi Bazzazzadehgan,1 Sebastian Bruera,2 Yinan Huang1 1Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS, 38677 USA; 2Section of Immunology, Allergy & Rheumatology, Baylor College of Medicine, Houston, TX, USACorrespondence: Yinan Huang, Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, Faser Hall 235, Oxford, MS, 38677, USA, Tel +1 (662) 915-2173, Email yhuang9@olemiss.eduObjective: This review summarized the real-world effectiveness outcomes of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) based on observational studies.Methods: A systematic review followed PRISMA guidelines, with searches conducted in PubMed, Embase, and CINAHL from each database’s inception to June 2, 2023. …”
Get full text
Article -
768
Current concepts of chronic gastritis and gastropathies: new international consensus RE.GA.IN
Published 2024-12-01“…In addition to the Sydney and Houston gastritis classifications, the six editions of the Maastricht Consensus (1996–2022) and the Kyoto Global Consensus deserve special attention, thanks to which broad agreements and significant scientific achievements became possible in the most controversial issues of the entire spectrum of gastritis, with a special emphasis on H.pylori gastritis, which accounts for more than 90 % of all forms of gastritis worldwide. …”
Get full text
Article -
769
Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
Published 2025-02-01“…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
Get full text
Article -
770
Grand Challenges at the Interface of Engineering and Medicine
Published 2024-01-01Get full text
Article -
771
Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening
Published 2025-02-01Get full text
Article -
772
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
Published 2025-12-01Get full text
Article -
773
The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function
Published 2025-01-01Get full text
Article -
774
-
775
-
776
Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma
Published 2024-12-01Get full text
Article -
777
-
778
Direct-Acting Oral Anticoagulants in the Management of Cerebral Venous Sinus Thrombosis—Where Do We Stand?
Published 2025-01-01Get full text
Article -
779
Optimizing electrode configurations for EEG mild cognitive impairment detection
Published 2025-01-01Get full text
Article -
780